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PCR = polymerase chain reaction.
Available online http://breast-cancer-research.com/content/3/5/285
Introduction
The search for occult metastatic cells in patients with
small breast tumours, which have been resected with
tumour-free margins, has attracted great interest during
the past decade. Early tumour cell dissemination is now
recognized as a cause of metastatic disease [1–3], which
is the leading cause of death from cancer in the Western
industrialized world. The immunocytochemical search for
such disseminated tumour cells in bone marrow was first
investigated in breast cancer [4]. It is thus perhaps some-
what ironic that the clinical significance of metastatic
breast cancer cells has remained controversial. The dis-
crepant results of clinical follow-up studies are best
explained by substantial methodological variations, study
populations of insufficient size, and short periods of clini-
cal follow up. Thus, the clinical applications for bone
marrow analysis in patients with solid tumours are still con-
troversially discussed [5,6].
Regarding methodological heterogeneity, a similar situa-
tion occurred in detection and evaluation of minimal resid-
ual disease in lymphoma, which, in an international effort,
was successfully overcome some 10 years ago [7]. In
patients with lymphoma standardized detection proce-
dures now contribute to a refined staging system, result-
ing in individualized treatment options and an improved
outcome for such patients [8]. This example clearly high-
lights the efforts that are now necessary in order to imple-
ment screening for occult metastatic carcinoma cells into
current risk classification systems and treatment protocols
for patients with breast cancer and other solid tumours.
The present commentary focuses on recent advances in
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Abstract
Approximately half of breast cancer patients with stage I–III disease will suffer metastatic disease
despite resection with tumour-free margins. In 30–40% of these patients, individual carcinoma cells
can already be detected at the time of primary therapy in cytological bone marrow preparations using
immunocytochemistry. Numerous prospective clinical studies have shown that the presence of occult
metastatic cells in bone marrow is prognostically relevant to patient survival. Only a few studies failed
to do so, thus stimulating a critical discussion on the methodology and clinical value of bone marrow
analysis. The potential for obtaining improved prognostic information on patient outcome, for
monitoring tumour cell eradication during adjuvant and palliative systemic therapy, and for specifically
targeting tumour biological therapies are intriguing clinical opportunities that may be afforded by bone
marrow analysis. Standardized and robust methodology is a prerequisite for clinical application of
these techniques, however.
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technologies for the detection of occult metastatic cells in
bone marrow in breast cancer patients.
Methods of tumour cell detection
Immunocytochemical and molecular approaches are cur-
rently being evaluated for their reliability and clinical utility
in detecting isolated metastatic cells in bone marrow of
breast cancer patients.
Immunocytochemistry
Data on bone marrow screening for breast cancer
micrometastasis have thus far been almost exclusively
based on immunocytochemical analyses. Although numer-
ous studies reported a strong association of the assay
used with prognosis [1–3,9–11], other investigators found
no such association of bone marrow micrometastases
with patient outcome [12–15], as summarized in Table 1.
Part of the reason for the discrepant results of clinical
follow-up studies is substantial methodological variation,
resulting in a wide range of detection rates (4–48%)
within comparable study populations [16].
The extreme diversity of antibodies used for identification of
epithelial cells (Table 1) is the major confounding variable,
and renders the results of most of the cited studies almost
incomparable. Because the specificity of the immunocyto-
chemical assay for detection of single tumour cells is one
of the key methodogical issues, noncarcinoma control
patients were included and evaluated continuously in our
studies [1,17], whereas most other groups did not report
such data. This issue is of particular importance in the case
of polymorphic epithelial mucins, such as epithelial mem-
brane antigen or mucin, which are also expressed by
haematopoietic precursor cells such as erythroblasts
[18–20]. In contrast, using validated antibodies directed
against cytokeratins as major constituents of epithelial
cells, no such cross-reactivity was observed. Although ille-
gitimate cytokeratin mRNA expression by haematopoietic
cells might be detected by sensitive polymerase chain
reaction (PCR) technologies, this problem is not relevant to
immunocytochemical approaches because cytokeratins are
very rarely detected in mesenchymal cells [1,18]. Thus, the
rare (<1%) occurrence of cytokeratin-positive aspirates in
noncarcinoma control patients [1] may reflect pathological
conditions, including chronic inflammations, or may indi-
cate spurious staining of aberrant plasmacytoid cells and
the presence of an as yet undiagnosed malignancy.
Additional justification for using cytokeratin-specific anti-
bodies in screening assays for occult breast carcinoma
cells can be derived from two recent studies. Multiple
chromosomal aberrations were detected in cytokeratin-
positive bone marrow micrometastases by interphase fluo-
rescent in situ hybridization analysis [21] and comparative
genome hybridization of genomic DNA [22], thus demon-
strating that these occult metastatic cells are indeed
tumour cells.
Even if anticytokeratin monoclonal antibodies on cytospin
preparations are used, however, the detection rate is still
affected by blood contamination of the bone marrow spec-
imen, the number of aspirates analyzed, and the number of
mononucleated bone marrow cells screened per aspira-
tion site [18]. Thus, the results of any immunocytochemi-
cal screening test for isolated carcinoma cells in bone
marrow largely depend on methodological issues. This
emphasizes the urgent need for an internationally stan-
dardized protocol as a prerequisite for implementation of
such screening into clinical practice. Taking recent
methodological and clinical studies into account, a stan-
Table 1
Immunocytochemical detection of occult metastatic cancer cells in bone marrow of breast cancer patients
Marker Preparation Patients (n) Detection rate (%) Prognostic value Reference
Mucin Biopsy 159 16 None [15]
Mucin Cell smears 25 48 None [14]
Mucin/CK Cell smears 71 38 None [13]
Mucin/CK Cell smears 49 37 DFS, OS [11]
Mucin/CK Cell smears 100 38 DFS, OS* [10]
Mucin Cell smears 727 43 DFS, OS* [3]
CK Biopsy 128 19 DFS, OS* [9]
CK18 Cytospins 581 28 None [12]
Mucin Cell smears 350 25 DFS, OS [2]
CK Cytospins 552 36 DDFS, OS* [1]
*Prognostic value confirmed by multivariate analysis. CK, cytokeratin; DDFS, distant disease-free survival; DFS, disease-free survival; OS, overall
survival.c
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dardized assay may consist of a specificity proven mono-
clonal antibody (ie A45-B/B3) and sufficient sample size
(ie 2 × 106 mononucleated cells) obtained from two aspi-
ration sites [1,18]. The use of automated screening
devices allows rapid and reproducible evaluation of the
immunocytochemical assay [23]. By using such a stan-
dardized immunocytochemical detection assay, pheno-
typing of single tumour cells by multiple staining
procedures allows further characterization of the actual
target cells for specific tumour biological therapies.
Polymerase chain reaction
Although increased sensitivity of the reverse transcription
(RT)-PCR technology as compared with immuncytochem-
istry is conceivable, the majority of studies conducted thus
far lack valid comparison with a true immunocytochemical
benchmark method, as mentioned above. In addition, as a
limiting factor in the detection of micrometastatic cells by
RT-PCR, illegitimate transcription of tumour-associated or
epithelia-specific genes was reported for haematopoietic
cells [24]. Because of the extreme genetic instability of
breast carcinoma cells, deficient expression of the marker
gene in micrometastatic tumour cells may lower the actual
sensitivity as compared with immunocytochemistry. In
addition, no distinction between viable and nonviable
tumour cells and no clear quantification of the tumour cell
load (low level versus high level mRNA/DNA expressors)
can be achieved. With quantitative RT-PCR techniques
that enable an estimate of the number of reference gene
transcripts in bone marrow cells in relation to the marker
gene transcripts (eg cytokeratin), a cutoff level can be
created to distinguish between malignant and nonmalig-
nant cells [25]. Prospective clinical studies that show
methodological validity and clinical relevance of these new
techniques in comparison with a standard immunocyto-
chemical assay are, however, needed before PCR-based
techniques can be considered for clinical application.
Conclusion
The current strategies for detection of occult metastatic
cells in bone marrow of breast cancer patients provide
intriguing clinical opportunities for improved tumour
staging, therapeutic targeting and, for the first time, the
possibility to monitor the efficacy of adjuvant systemic
therapy [26,27]. At present we feel that there is a need for
concerted international activity to implement standardized
immunocytochemical procedures that are already avail-
able, which may then serve as a ‘gold standard’ with
which to compare novel diagnostic approaches. The
development of new PCR-based methods may increase
assay sensitivity and help to reduce the influence of
varying levels of expertise among observers, but these
methods still require validation in clinical follow-up studies.
In order to obtain a higher level of evidence [28] regarding
the prognostic and predictive impact of occult metastatic
cells in the bone marrow of breast cancer patients, further
clinical studies that apply the available methodological
improvements are urgently needed.
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